|
Northwest Biotherapeutics |
|
|
7600 Wisconsin Ave, Suite 750
Bethesda, MD 20814 USA
phone:240-497-9024
fax:(425) 608-3009
|
|
| Symbol |
NWBO.OB |
| Exchange |
OTCBB |
| Founded |
1996 |
| Employees |
|
|
|
| www.nwbio.com
|
|
| Research Sector |
Biotech Specialty Pharma |
|
 |
| Summary Description |
| Immunotherapy products for cancer treatment |
|
| Management |
| Linda F. Powers, Chairperson of the Board; Alton L. Boynton, President, Chief Executive Officer, Secretary, Director; Marnix L. Bosch, Chief Technical Officer |
| |
|
|
|
|
|
|
|
| Keywords |
| oncology, brain, Urology, prostate, urinary, bladder, erectile, cancer, mouse cell, immunotherapy |
|
|
|
| Description |
|
Northwest Biotherapeutics Inc. is developing immunotherapy products that generate and enhance immune system responses to treat cancer. The Company’s approach to developing therapies lies in its expertise in the biology of dendritic cells, which naturally activate the immune system and have been shown in clinical trials to significantly extend the time of survival for cancer patients, with no debilitating side effects. Northwest Biotherapeutics’ platform technology, DCVax®, involves extracting a patient’s dendritic cells from the body, loading them with tumor biomarkers or “antigens” in order to create a personalized therapeutic vaccine, and injecting these cells back into the patient to initiate a potent immune response against cancer cells. The Company’s lead product candidate, DCVax®-L, is in Phase II trials for targeting Glioblastoma Multiforme, the most lethal form of brain cancer. DCVax®-Prostate, which targets late-stage prostate cancer, has received FDA clearance to commence a Phase III clinical trial. This earlier-stage biotechnology company is also developing ProstaView™, an experimental monoclonal antibody-based technology that enables the in vivo diagnostic imaging of metastatic prostate cancer, as well as CXCR4, an experimental monoclonal antibody therapy that targets a functional chemokine receptor highly expressed in several cancer types. |
|
| Products / Services |
DCVax-Brain HuRx-Prostate
|
|
| Technology / Differentiation |
| DCVax is a dendritic cell-based cancer immunotherapy platform. DCVax therapies are designed to safely elicit potent immune responses that eliminate cancer cells.
HuRx is a monoclonal antibody-based cancer therapy platform. HuRx product candidates are based on monoclonal antibodies that do not contain mouse proteins, like traditional monoclonal antibodies, and are known as humanized and fully human monoclonal antibodies. In partnership with Medarex, Inc., they co-developed their lead HuRx product candidate, HuRx-Prostate, which is a fully human monoclonal antibody-based therapy for the treatment of prostate cancer. |
|
| Market / Customers |
Currently approved cancer treatments are frequently ineffective and can cause undesirable side effects.
|
|
| Status |
| DCVax-Brain, has been granted an Orphan Drug designation and received clearance from the FDA, to commence a Phase II clinical trial for glioblastoma, a lethal form of brain cancer. This trial is currently inactive, pending the company securing additional financing. HuRx-Prostate is entering a Phase I clinical trial and has been acquired by Medarex. |
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members
